Overview

Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer

Status:
Terminated
Trial end date:
2019-03-06
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cadexomer iodine
Iodine